Journal Article

Epstein–Barr virus infections: prospects for treatment

Edward Gershburg and Joseph S. Pagano

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 56, issue 2, pages 277-281
Published in print August 2005 | ISSN: 0305-7453
Published online July 2005 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dki240
Epstein–Barr virus infections: prospects for treatment

Show Summary Details

Preview

Epstein–Barr virus (EBV) causes infectious mononucleosis and oral hairy leucoplakia, and is associated with a number of malignancies. There are, however, no regulatory agency-approved treatments for EBV-related diseases. Several antiviral drugs inhibit replication of EBV in cell culture including acyclic nucleoside and nucleotide analogues and pyrophosphate analogues, all of which inhibit the EBV DNA polymerase. Despite their potency in vitro, these drugs have limited use in vivo for treatment of acute primary EBV infection as well as EBV-associated malignancies for several reasons. Here we discuss novel anti-EBV compounds, including maribavir, potentially useful for the treatment of acute EBV infections. A number of experimental approaches for treatment of EBV-related malignancies that are not susceptible to conventional antiviral drug treatment are also discussed.

Keywords: EBV; infectious mononucleosis; antiviral drugs

Journal Article.  4162 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.